Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 12/2021

01-12-2021 | Migraine | Original Article

Effects of the onabotulinumtoxinA follow-up delay in migraine course during the COVID-19 lockdown

Authors: Alicia Gonzalez-Martinez, Álvaro Planchuelo-Gómez, Ángel L Guerrero, David García-Azorín, Sonia Santos-Lasaosa, María Pilar Navarro-Pérez, Paula Odriozola-González, María Jesús Irurtia, Sonia Quintas, Rodrigo de Luis-García, Ana Beatriz Gago-Veiga

Published in: Neurological Sciences | Issue 12/2021

Login to get access

Abstract

Background

Face-to-face procedures have been postponed during COVID-19 pandemic. We aim to evaluate the impact of onabotulinumtoxinA follow-up delay in migraine during COVID-19 pandemic.

Methods

Subjective worsening, intensity of migraine attacks, and frequency of headache and migraine were retrospectively compared between patients with unmodified and interrupted onabotulinumtoxinA follow-up in Headache Units.

Results

We included 67 patients with chronic migraine or high-frequency episodic migraine under onabotulinumtoxinA treatment, 65 (97.0%) female, 44.5 ± 12.1 years old. Treatment administration was voluntarily delayed in 14 (20.9%) patients and nine (13.4%) were unable to continue follow-up. Patients with uninterrupted follow-up during lockdown presented 7.6 and 8.1 less monthly days with headache (adjusted p = 0.017) and migraine attacks (adjusted p = 0.009) compared to patients whose follow-up was interrupted, respectively.

Conclusion

Involuntary delay of onabotulinumtoxinA follow-up in patients with migraine due to COVID-19 pandemic was associated with a higher frequency of headache and migraine attacks. Safe administration of onabotulinumtoxinA during lockdown should be promoted.
Appendix
Available only for authorised users
Literature
1.
Ali A (2020) Delay in onabotulinumtoxinA treatment during the COVID-19 pandemic—perspectives from a virus hotspot. Headache. 60(6):1183–1186CrossRef
2.
López-Bravo A, García-Azorín D, Belvís R, González-Oria C, Latorre G, Santos-Lasaosa S et al (2020) Impact of the COVID-19 pandemic on headache management in Spain: an analysis of the current situation and future perspectives. Neurol (Engl Ed) 35(6):372–380
3.
Santos-Lasaosa S, Porta-Etessam J (2020) OnabotulinumtoxinA infiltration and nerve blocks in patients with headache and neuralgia: safety recommendations to prevent SARS-CoV-2 infection. Neurol (Engl Ed) 35(5):291–294
4.
Szperka CL, Ailani J, Barmherzig R, Klein BC, Minen MT, Halker Singh RB et al (2020) Migraine care in the era of COVID-19: clinical pearls and plea to insurers. Headache. 60(5):833–842CrossRef
5.
Silvestro M, Tessitore A, Tedeschi G, Russo A (2020) Migraine in the time of COVID-19. Headache. 60(5):988–989CrossRef
6.
Headache Classification Committee of the International Headache Society (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 38(1):1–211CrossRef
7.
Loder E, Burch R (2012) Measuring pain intensity in headache trials: which scale to use? Cephalalgia. 32(3):179–182CrossRef
8.
Horowitz MJ, Wilner N, Alvarez W (1979) Impact of Event Scale: a measure of subjective stress. Psychosom Med 41(3):209–218CrossRef
9.
Porta-Etessam J, Gonzalez-Garcia N, Matias-Guiu JA, Montero-Escribano P, Matías-Guiu J (2020) Should we adapt the prescription criteria for specific treatments for migraine due to the COVID-19 pandemic? Headache. 60(7):1448–1449CrossRef
10.
Dressler D, Adib SF (2020) Botulinum toxin therapy in the SARS-CoV-2 pandemic: patient perceptions from a German cohort. J Neural Transm 127(9):1271–1274CrossRef
11.
Erro R, Scannapieco S, Russo M, Picillo M, Barone P (2021) Impact of COVID-19 on neurological patients attending a botulinum toxin service. Neurol Sci 42(2):433–435CrossRef
12.
Gonzalez-Martinez A, Rodríguez Vázquez E, de la Red Gallego H, García-Azorín D, Gallego de La Sacristana M, Guerrero Peral ÁL et al (2020) Association between personality traits and onabotulinumtoxinA response in patients with chronic migraine. Headache. 60(1):153–161CrossRef
13.
Boudreau GP, Grosberg BM, McAllister PJ, Lipton RB, Buse DC (2015) Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: an open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety. Int J Gen Med 8:79–86CrossRef
14.
Marmura MJ (2018) Triggers, protectors, and predictors in episodic migraine. Curr Pain Headache Rep 22(12):81CrossRef
15.
Consonni M, Telesca A, Grazzi L, Cazzato D, Lauria G (2021) Life with chronic pain during COVID-19 lockdown: the case of patients with small fibre neuropathy and chronic migraine. Neurol Sci 42(2):389–397CrossRef
16.
Minen MT, Begasse De Dhaem O, Kroon Van Diest A, Powers S, Schwedt TJ, Lipton R et al (2016) Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry 87(7):741–749CrossRef
17.
Baskin SM, Lipchik GL, Smitherman TA (2006) Mood and anxiety disorders in chronic headache. Headache. 46(Suppl 3):S76–S87CrossRef
18.
Planchuelo-Gómez Á, Odriozola-González P, Irurtia MJ, de Luis-García R (2020) Longitudinal evaluation of the psychological impact of the COVID-19 crisis in Spain. J Affect Disord 277:842–849CrossRef
19.
Altamura C, Cevoli S, Aurilia C, Egeo G, Fofi L, Torelli P et al (2020) Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the PandeMig study. Neurol Sci 41(12):3385–3389CrossRef
Metadata
Title
Effects of the onabotulinumtoxinA follow-up delay in migraine course during the COVID-19 lockdown
Authors
Alicia Gonzalez-Martinez
Álvaro Planchuelo-Gómez
Ángel L Guerrero
David García-Azorín
Sonia Santos-Lasaosa
María Pilar Navarro-Pérez
Paula Odriozola-González
María Jesús Irurtia
Sonia Quintas
Rodrigo de Luis-García
Ana Beatriz Gago-Veiga
Publication date
01-12-2021
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 12/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-021-05180-8

Other articles of this Issue 12/2021

Neurological Sciences 12/2021 Go to the issue

Correction

Correction to: Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry cohort study (RelevarEM)

Brief Communication

Clinical and radiological features of cerebral amyloid angiopathy-related inflammation

Original Article

Cancer risk for multiple sclerosis patients treated with azathioprine and disease-modifying therapies: an Italian observational study

COVID-19

Qualitative smell/taste disorders as sequelae of acute COVID-19

Original Article

The effect of ketogenic diet on thyroid functions in children with drug-resistant epilepsy

Original Article

The relationship between attention and static balance disturbance in patients with Parkinson’s disease